Achieving high maturity and functionality in in vitro skeletal muscle models is essential for advancing our understanding of muscle biology, disease mechanisms, and drug discovery. However, current models struggle to fully recapitulate key features such as sarcomere structure, muscle fiber composition, and contractile function while also ensuring consistency and rapid production. Adult stem cells residing in muscle tissue are known for their powerful regenerative potential, yet tissue-derived skeletal muscle organoids have not been established. In this study, we introduce droplet-engineered skeletal muscle organoids derived from primary tissue using cascade-tubing microfluidics. These droplet-engineered organoids (DEOs) exhibit high maturity, including well-developed striated sarcomeres, spontaneous and stimulated contractions, and recapitulation of parental muscle fiber types. Notably, DEOs are produced in just 8 d without the need for primary cell culture—substantially accelerating the 50- to 60-d process required by classical organoid models. Additionally, the cascade-tubing microfluidics platform enables high-throughput production of hundreds of uniform DEO replicates from a small tissue sample, providing a scalable and reproducible solution for skeletal muscle research and drug screening.
| • | ASC-derived SkMOs with sarcomere and muscle fiber type recovery: The majority of previous organoid studies have employed PSCs, which present considerable challenges due to their prolonged culture periods, suboptimal phenotype recapitulation, and limited prospects for clinical application. We effectively utilized ASCs to rapidly establish sarcomeres and maintain type I, type IIA, and type IIB muscle fibers within the organoids. This achievement is crucial for replicating the functional characteristics of muscle in vitro and underscores the potential of DEOs for muscle disease modeling and therapeutic applications. |
| • | Contractile functional SkMOs: One of the major advancements of the model herein is its stable contractility. Both spontaneous contractions and electrically induced patterned contractions were observed in DEOs, demonstrating the essential contractile functionality required for muscle models. Typically, contractile activity begins around day 6 and is stably maintained thereafter. |
| • | High-throughput production in 8 d: The engineered CTM system enabled the high-throughput production of DEOs. Remarkably, gastrocnemius isolated from one mouse could generate over 500 DEOs with a consistent size and reproducible outcomes in just 8 d, without the need for primary culture. This large production capacity opens new possibilities for human-patient-derived SkMOs in drug screening. Additionally, the scalability of DEO production holds potential for a range of applications, including the assembly of larger muscle tissues by migration-based assembly (Fig. |
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |